Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.
COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.
